Shaff Eric D. 4
4 · Seres Therapeutics, Inc. · Filed Nov 18, 2025
Insider Transaction Report
Form 4
Shaff Eric D.
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-15+331→ 11,330 total - Sale
Common Stock
2025-11-15$17.30/sh−217$3,754→ 11,113 total - Exercise/Conversion
Restricted Stock Units
2025-11-15−390→ 1,954 total→ Common Stock (390 underlying) - Exercise/Conversion
Common Stock
2025-11-15+390→ 10,999 total - Exercise/Conversion
Restricted Stock Units
2025-11-15−331→ 2,989 total→ Common Stock (331 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F3]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- [F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.